Harriet Worthington

Harriet Worthington is an associate in Goodwin’s Technology and Life Sciences groups in the firm’s London office. Harriet advises clients on a broad range of corporate matters. She has particular experience advising on private equity and venture capital investments and exits, mergers and acquisitions, corporate financings and reorganisations, as well as general corporate matters. Harriet advises clients through every stage of the corporate life cycle.

Venture Capital Financings

• Advised General Catalyst on the €150 million Series E financing of ICEYE.
• Advised General Catalyst, Bertelsmann and Meridian Health Ventures on Phare Health’s acquisition by R1.
• Advised General Catalyst on the $67.5 million Series B financing of Lean Technologies.
• Advised Tenpoint Therapeutics, a global biotechnology company, on its $235 million Series B financing and credit facility in connection with the commercialization of YUVEZZI™, the first and only dual-agent eye drop for the treatment of presbyopia.
• Advised Adcendo, a clinical-stage biotechnology company, on the closing of its oversubscribed $135 million Series B financing round.
• Advised Lupa, an AI-powered platform designed to enhance the efficiency of veterinary practices, on its $4 million seed financing round and on its $20 million Series A financing round led by Singular.
• Advised Scalpel AI on its £3.8 million funding round led by Mercia Ventures. Scalpel AI is an AI platform for the surgical supply chain, enhancing productivity and reducing errors in surgical workflows by automatically identifying and classifying surgical inventory without tags.

M&A

• Advised on the sale of Tessian to Proofpoint.